Login Register Cart 0
Generic placeholder image

Mini-Reviews in Organic Chemistry

Editor-in-Chief

ISSN (Print): 1570-193X
ISSN (Online): 1875-6298

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Comprehensive Insight into Synthetic Strategies of Enigmol and Its Analogs as Therapeutic Agents

Author(s): Parleen Kaur and Vasundhara Singh*

Volume 20, Issue 7, 2023

Published on: 20 August, 2022

Page: [675 - 686] Pages: 12

DOI: 10.2174/1570193X19666220820115630

Price: $65

Abstract

1-Deoxysphingolipids are a class of sphingolipids which lacks the primary hydroxyl group (C1-OH). Hence, it does not get converted/degraded to complex corresponding products like sphingosine- 1-phosphate (SIP), a pro-mitotic. Enigmol, an orally bioavailable 1-deoxyphingolipid has shown potential against various different types of cancer cells along with impressive cytotoxic/ antiproliferative properties. Due to its unique structural properties, Enigmol and its analogs have attracted considerable attention from synthetic organic chemists. This review provides an overview of all the synthetic approaches being followed for the synthesis of Enigmol and its structural analogs.

Keywords: Sphingolipid, 1-deoxysphingolipid, enigmol, aldol reaction, cross metathesis reaction, alkyne zipper reaction

« Previous Next »
Graphical Abstract

[1]
Takabe, K.; Paugh, S.W.; Milstien, S.; Spiegel, S. “Inside-out” signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol. Rev., 2008, 60(2), 181-195.
[http://dx.doi.org/10.1124/pr.107.07113] [PMID: 18552276]
[2]
Pruett, S.T.; Bushnev, A.; Hagedorn, K.; Adiga, M.; Haynes, C.A.; Sullards, M.C.; Liotta, D.C.; Merrill, A.H., Jr Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. J. Lipid Res., 2008, 49(8), 1621-1639.
[http://dx.doi.org/10.1194/jlr.R800012-JLR200] [PMID: 18499644]
[3]
Tani, M.; Ito, M.; Igarashi, Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell. Signal., 2007, 19(2), 229-237.
[http://dx.doi.org/10.1016/j.cellsig.2006.07.001] [PMID: 16963225]
[4]
Snook, C.; Jones, J.; Hannun, Y. Sphingolipid-binding proteins. Biochim. biophys. acta (BBA) –. Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 2006, 1761(8), 927-946.
[http://dx.doi.org/10.1016/j.bbalip.2006.06.004]
[5]
Pyne, N.J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10(7), 489-503.
[http://dx.doi.org/10.1038/nrc2875] [PMID: 20555359]
[6]
Allende, M.L.; Sasaki, T.; Kawai, H.; Olivera, A.; Mi, Y.; van Echten-Deckert, G.; Hajdu, R.; Rosenbach, M.; Keohane, C.A.; Mandala, S.; Spiegel, S.; Proia, R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem., 2004, 279(50), 52487-52492.
[http://dx.doi.org/10.1074/jbc.M406512200] [PMID: 15459201]
[7]
Kennedy, A.J.; Mathews, T.P.; Kharel, Y.; Field, S.D.; Moyer, M.L.; East, J.E.; Houck, J.D.; Lynch, K.R.; Macdonald, T.L. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J. Med. Chem., 2011, 54(10), 3524-3548.
[http://dx.doi.org/10.1021/jm2001053] [PMID: 21495716]
[8]
Sachs, C.W.; Safa, A.R.; Harrison, S.D.; Fine, R.L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J. Biol. Chem., 1995, 270(44), 26639-26648.
[http://dx.doi.org/10.1074/jbc.270.44.26639] [PMID: 7592889]
[9]
Cohen, J.; Khatri, B.; Barkhof, F.; Comi, G.; Hartung, H.; Montalban, X.; Pelletier, J.; Stites, T.; Ritter, S.; von Rosenstiel, P.; Tomic, D.; Kappos, L. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. Neurol. Neurosurg. Psychiat., 2016, 87, 468-475.
[10]
Lexicon Pharmaceuticals. Available from: http://www.lexicon-genetics.com/pipeline/lx2931.html
[11]
French, K.J.; Zhuang, Y.; Maines, L.W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J.J.; Green, C.L.; Keller, S.N.; Smith, C.D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther., 2010, 333(1), 129-139.
[http://dx.doi.org/10.1124/jpet.109.163444] [PMID: 20061445]
[12]
Dellafiora, L.; Galaverna, G.; Dall’Asta, C. Mechanisms of fumonisin B1 toxicity: A computational perspective beyond the ceramide synthases inhibition. Chem. Res. Toxicol., 2018, 31(11), 1203-1212.
[http://dx.doi.org/10.1021/acs.chemrestox.8b00188] [PMID: 30346146]
[13]
Abad, J.L.; Nieves, I.; Rayo, P.; Casas, J.; Fabriàs, G.; Delgado, A. Straightforward access to spisulosine and 4,5-dehydrospisulosine stereoisomers: Probes for profiling ceramide synthase activities in intact cells. J. Org. Chem., 2013, 78(12), 5858-5866.
[http://dx.doi.org/10.1021/jo400440z] [PMID: 23679346]
[14]
Rinehart, K.L.; Fregeau, N.L.; Warwick, R.A.; Garcia Gravalos, D.; Avila, J.; Faircloth, G.T. Spisulosine compounds having antitumor activity., PCT WO9952521, 1999.
[15]
Rinehart, K.L.; Warwick, R.A.; Avila, J.; Fregeau, G.N.L.; Garcia, G.D.; Faircloth, G.T. Antitumor spisulosine compounds US 6800661, 2004.
[16]
Martinková, M.; Gonda, J.; Jacková, D. Simple marine 1-deoxysphingoid bases: Biological activity and syntheses. Tetrahedron Asymmetry, 2016, 27(24), 1187-1212.
[http://dx.doi.org/10.1016/j.tetasy.2016.10.009]
[17]
Duan, J.; Merrill, A.H., Jr 1-Deoxysphingolipids encountered exogenously and made de novo: Dangerous mysteries inside an enigma. J. Biol. Chem., 2015, 290(25), 15380-15389.
[http://dx.doi.org/10.1074/jbc.R115.658823] [PMID: 25947379]
[18]
Zuellig, R.A.; Hornemann, T.; Othman, A.; Hehl, A.B.; Bode, H.; Güntert, T.; Ogunshola, O.O.; Saponara, E.; Grabliauskaite, K.; Jang, J.H.; Ungethuem, U.; Wei, Y.; von Eckardstein, A.; Graf, R.; Sonda, S. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes, 2014, 63(4), 1326-1339.
[http://dx.doi.org/10.2337/db13-1042] [PMID: 24379346]
[19]
Schmelz, E.M.; Roberts, P.C.; Kustin, E.M.; Lemonnier, L.A.; Sullards, M.C.; Dillehay, D.L.; Merrill, A.H., Jr Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res., 2001, 61(18), 6723-6729.
[PMID: 11559543]
[20]
Park, S.R.; Cho, H.J.; Moon, K.J.; Chun, K.H.; Kong, S.Y.; Yoon, S.S.; Lee, J.S.; Park, S. Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60. Leuk. Lymphoma, 2010, 51(1), 132-145.
[http://dx.doi.org/10.3109/10428190903383419] [PMID: 20001229]
[21]
Bushnev, A.S.; Baillie, M.T.; Holt, J.J.; Menaldino, D.S.; Merrill, A.H.; Liotta, D.C. An efficient asymmetric synthesis of Enigmols (1-deoxy-5-hydroxysphingoid bases), an important class of bioactive lipid modulators. ARKIVOC, 2010, 8(8), 263-277.
[http://dx.doi.org/10.3998/ark.5550190.0011.818]
[22]
a) Aceña, J. L.; Adrio, J.; Cuevas, C.; Gallego, P.; Manzanares, I.; Munt, S.; Rodriguez, I. Antitumoral compounds. WO 94357A1, 2001.;
b) Aceña, J.L.; Adrio, J.; Cuevas, C.; Gallego, P.; Manzanares, I.; Munt, S ; Rodriguez, I Antitumoral compounds 0048834A1, 2004.
[23]
a) Aiello, A.; Fattorusso, E.; Giordano, A.; Menna, M.; Navarrete, C.; Muñoz, E. Clavaminols A-F, novel cytotoxic 2-amino-3-alkanols from the ascidian Clavelina phlegraea. Bioorg. Med. Chem., 2007, 15(8), 2920-2926.
[http://dx.doi.org/10.1016/j.bmc.2007.02.015] [PMID: 17336534];
b) Aiello, A.; Fattorusso, E.; Giordano, A.; Menna, M.; Navarrete, C.; Muñoz, E. Clavaminols G–N, six new marine sphingoids from the Mediterranean ascidian Clavelina phlegraea. Tetrahedron, 2009, 65(22), 4384-4388.
[http://dx.doi.org/10.1016/j.tet.2009.03.056]
[24]
Archer, S.G.; Csatayová, K.; Davies, S.G.; Fletcher, A.M.; Roberts, P.M.; Thomson, J.E. Asymmetric synthesis of N,O-diacetyl-3-epi-xestoaminol C: Structure and absolute configuration confirmation of 3-epi-xestoaminol C. Tetrahedron Lett., 2016, 57(11), 1270-1272.
[http://dx.doi.org/10.1016/j.tetlet.2016.02.021]
[25]
Seiferlein, M.; Humpf, H.U.; Voss, K.A.; Sullards, M.C.; Allegood, J.C.; Wang, E.; Merrill, A.H. Jr Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites. Mol. Nutr. Food Res., 2007, 51(9), 1120-1130.
[http://dx.doi.org/10.1002/mnfr.200700118] [PMID: 17729221]
[26]
Symolon, H.; Bushnev, A.; Peng, Q.; Ramaraju, H.; Mays, S.G.; Allegood, J.C.; Pruett, S.T.; Sullards, M.C.; Dillehay, D.L.; Liotta, D.C.; Merrill, A.H. Jr Enigmol: A novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer. Mol. Cancer Ther., 2011, 10(4), 648-657.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0754] [PMID: 21398423]
[27]
Wiseman, J.M.; McDonald, F.E.; Liotta, D.C. 1-Deoxy-5-hydroxysphingolipids as new anticancer principles: An efficient procedure for stereoselective syntheses of 2-amino-3,5-diols. Org. Lett., 2005, 7(15), 3155-3157.
[http://dx.doi.org/10.1021/ol050829o] [PMID: 16018609]
[28]
Esteve, J.; Lorente, A.; Romea, P.; Urpí, F. Ríos‐Luci, C.; Padrón, J.M. Synthesis and biological evaluation of 1-deoxy-5-hydroxysphingosine derivatives. Eur. J. Org. Chem., 2011, 5(5), 960-967.
[http://dx.doi.org/10.1002/ejoc.201001268]
[29]
Chen, K.M.; Hardtmann, G.E.; Prasad, K. Repič O.; Shapiro, M.J. 1,3- diastereoselective reduction of β-hydroxyketones utilizing alkoxydialkylboranes. Tetrahedron Lett., 1987, 28(2), 155-158.
[http://dx.doi.org/10.1016/S0040-4039(00)95673-9]
[30]
Garnier-Amblard, E.C.; Mays, S.G.; Arrendale, R.F.; Baillie, M.T.; Bushnev, A.S.; Culver, D.G.; Evers, T.J.; Holt, J.J.; Howard, R.B.; Liebeskind, L.S.; Menaldino, D.S.; Natchus, M.G.; Petros, J.A.; Ramaraju, H.; Reddy, G.P.; Liotta, D.C. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. ACS Med. Chem. Lett., 2011, 2(6), 438-443.
[http://dx.doi.org/10.1021/ml2000164] [PMID: 24900327]
[31]
McDonald, F.E.; Pereira, C.L. Synthesis of 2-amino-3,5-diols via stereospecific crotyl transfer and regioselective aminohydroxylation. Synthesis, 2012, 44(23), 3639-3648.
[http://dx.doi.org/10.1055/s-0032-1316805]
[32]
Srivastava, N.; Ha, H.J. Highly efficient and stereoselective mukaiyama aldol reaction with chiral aziridine‐2‐carboxaldehyde and its synthetic applications. Asian J. Org. Chem., 2021, 11(1)
[http://dx.doi.org/10.1002/ajoc.202100567]
[33]
Dougherty, A.M.; McDonald, F.E.; Liotta, D.C.; Moody, S.J.; Pallas, D.C.; Pack, C.D.; Merrill, A.H. Synthesis of 1-deoxysphingosine derivatives with conformationally restricted pyrrolidinediol head groups. Org. Lett., 2006, 8(4), 649-652.
[http://dx.doi.org/10.1021/ol052839v] [PMID: 16468733]
[34]
Meyer, E.V.; Holt, J.J.; Girard, K.R.; Ballie, M.T.; Bushnev, A.S.; Lapp, S.; Menaldino, D.S.; Arrendale, R.F.; Reddy, G.P.; Evers, T.J.; Howard, R.B.; Culver, D.G.; Liotta, D.C.; Galinski, M.R.; Natchus, M.G. Sphingolipid analogues inhibit development of malaria parasites. ACS Med. Chem. Lett., 2011, 3(1), 43-47.
[http://dx.doi.org/10.1021/ml2002136] [PMID: 24900369]
[35]
Miller, E.J.; Mays, S.G.; Baillie, M.T.; Howard, R.B.; Culver, D.G.; Saindane, M.; Pruett, S.T.; Holt, J.J.; Menaldino, D.S.; Evers, T.J.; Reddy, G.P.; Arrendale, R.F.; Natchus, M.G.; Petros, J.A.; Liotta, D.C. Discovery of a fluorinated enigmol analog with enhanced in vivo pharmacokinetic and anti-tumor properties. ACS Med. Chem. Lett., 2016, 7(5), 537-542.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00113] [PMID: 27190606]
[36]
Pemha, R.; Pegnyemb, D.E.; Mosset, P. Synthesis of (2S,3R,5R)-2-azido-3,5-dihydroxynonadecane sphingolipid analogue. Synthesis, 2020, 52(17), 2572-2578.
[http://dx.doi.org/10.1055/s-0040-1707397]
[37]
Menaldino, D.S.; Bushnev, A.; Sun, A.; Liotta, D.C.; Symolon, H.; Desai, K.; Dillehay, D.L.; Peng, Q.; Wang, E.; Allegood, J.; Trotman-Pruett, S.; Sullards, M.C.; Merrill, A.H., Jr Sphingoid bases and de novo ceramide synthesis: Enzymes involved, pharmacology and mechanisms of action. Pharmacol. Res., 2003, 47(5), 373-381.
[http://dx.doi.org/10.1016/S1043-6618(03)00054-9] [PMID: 12676511]

Rights & Permissions Print Cite
Article Metrics
1
© 2025 Bentham Science Publishers | Privacy Policy